Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
775 Initial results from dose escalation of a phase 1/2 first-in-human, open label study of AU-007, a monoclonal antibody that binds to IL-2 and prevents its binding to CD25, in patients with solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.